The Celgene and Pharmstandard-backed immuno-oncology company has raised almost $140m in equity financing in under three years.

Tasly Pharmaceuticals, a major participant in the liver disease therapy developer's $55m series A round, has reinvested as part of its series B round.

Indigo Diabetes, a spinout of Ghent University and Imec, has raised the capital from a consortium of investors that included university venturing fund Qbic.

Sun Pharmaceuticals has picked up a 14.6% stake in SCPharmaceuticals, which had received $16m in a 2014 round co-led by Lundbeckfond Ventures.

The medical researcher is combining its Mayo Clinic Ventures unit with its Office of Business Development, through the newly formed Department of Business Development.

Patient monitoring technology provider Healthsense has been acquired by GreatCall after raising about $23m in equity from investors including Merck & Co.

Rex Health Ventures-backed Veran has raised debt and equity financing that will be used to commercialise the company's lung cancer diagnostics system.

Antibody therapy developer Northern Biologics has extended its series A round and merged with oncology treatment developer Mosaic Biomedicals.

Legend Holdings-backed Berry Genomics will list through a reverse merger with auto parts maker Chengdu Tianxing Instrument & Meter in a deal that values it at $619m.